Electromed (ELMD) Keeps Growing While Wall Street Barely Notices

Electromed (ELMD) has reported strong fiscal fourth-quarter results, marking its fifteenth consecutive quarter of year-over-year revenue and profit growth. Net revenue reached $19.4 million, an 11.6% increase from the previous year, while diluted earnings per share rose to $0.39 from $0.25. Home care revenue accounted for $17.7 million, up 15.2% year-over-year, contributing to the overall growth.

Management estimates that around 1 million Americans have bronchiectasis, but only about 16% use high-frequency chest wall oscillation therapy, leaving a significant potential market untouched. Payer contracts have expanded, with 87% of US covered lives under contract, and the company added 6 million covered lives and 40 new payer agreements during the year.

However, hospital revenue declined by 29% in the fourth quarter, attributed to a less predictable sales cycle. Non-home care business growth was only 6.7% for the year, suggesting that most of Electromed's growth is coming from home care. SG&A expenses grew by 8.7% to $42.7 million, driven by increased sales, marketing, and reimbursement compensation.

Operating cash flow declined to $9.7 million for fiscal 2026, despite a sharp rise in net income. The company is expected to retire CEO James Cunniff by April 2027, and there is no named successor yet. Hedge fund ownership of Electromed has increased, with 13 funds now holding shares, while short interest remains low at 1.12% of float.

Despite the impressive growth streak, the reliance on a single growth engine and the uncertainty surrounding the leadership transition pose some risks to the investment case.